Friday, 20 Apr 2018

You are here

Pregnancy in Lupus

Today’s session by Fischer-Betz Rebecca from Germany was very interesting. Young patients with systemic lupus erythematosus (SLE) get diagnosed before they have completed their families. About 30 or 40 years ago, most rheumatologists were not recommending pregnancy for their lupus patients. However, in recent times, outcomes have considerably improved. We should keep in mind that SLE does increase risk of pregnancy complications for both the mother and the child as compared to healthy women. For mothers, it increases risk of SLE flares, preeclampsia and overall medical complications. For the children, the complications include late and early fetal loss, growth retardation, neonatal lupus and congenital heart blocks.

Complications during pregnancy increase with these risk factors:

  • Active disease within 6 months prior to conception

  • Active lupus nephritis

  • Preexisting renal disease, especially renal damage

  • Associated antiphopholipid antibody syndrome

  • Chronic hypertension

  • Use of glucocorticoids (> 10-20 mg /day)

  • Discontinuation of hydroxychloroquine

Often even high-risk SLE patients get pregnant due to a strong desire to conceive.  Cornerstones of care of SLE patients who get pregnant are awareness of the disease and complications both by the physicians and patients. A multidisciplinary team approach should be used and importance of needed immunosuppression must be emphasized.

 

Pre-pregnancy counselling and appropriate management during early pregnancy improves pregnancy outcomes significantly.  Individual patients should be risk stratified and informed about them. All medications must be reviewed and comorbidities must be identified and treated. EULAR guidelines published in 2016 are useful.

Add new comment

More Like This

The RheumNow Week in Review – Vitamin D Snark Report (4.20.18)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.  A second life for Syk kinase, Vitamin D talk, VTE, regulatory hearings and the Lupus clinic edge.

RheumNow Week in Review - Do you Dig Shingrix? (4.6.2018)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Highlights includes manpower shortfalls, comorbidities in AA Lupus, certolizumab pregnancy safety, which Shingles vaccine is best and the power of combination biologics in severe refractory  SLE.

"Breakthrough" Drug Designation by the FDA

The current issue of the NEJM reviews the Food and Drug Administration (FDA) “breakthrough therapy” designation that was introduced in 2012 to expedite testing and approval of medications that were intended to treat serious or life-threatening conditions.  This status is granted when preliminary evidence with a new drug suggests substantial benefits over existing therapies for these unfortunate conditions.

ACR Projects Significant Manpower Shortages for 2030

Arthritis & Rheumatology has published the results of the 2015 Workforce Study of Rheumatology Specialists, and estimates a current shortage (demand > supply) of 700 (12.9%) full-time rheumatologists and that this deficit will worsen (102%) to 4133 FTE by 2030.

RheumNow Week in Review -The Temporal Artery Biopsy Letdown (4.6.2018)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. News on the cost of RA care, infections on planes, CV events and Sacroiliitis in IBD, NXP-2 antibodies and calcinosis and rituximab in myositis ILD patients.